

CITATION REPORT

List of articles citing

Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers

DOI: 10.1186/1471-230x-9-95
BMC Gastroenterology, 2009, 9, 95.

Source: <https://exaly.com/paper-pdf/46301462/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
233	Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. <i>BMC Gastroenterology</i> , 2010 , 10, 110	3	50
232	Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. 2010 , 2, 19		137
231	From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome. 2010 , 16, 363-73		35
230	Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role. 2010 , 24, 961-75, ix		21
229	Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. 2010 , 156, 3205-3215		198
228	The intestinal microbiota and chronic disorders of the gut. 2011 , 8, 523-31		230
227	Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. 2011 , 301, G799-807		192
226	Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. 2011 , 141, 1782-91		464
225	Potential biomarkers. 2011 , 40, 121-39		21
224	A novel method for determining microflora composition using dynamic phylogenetic analysis of 16S ribosomal RNA deep sequencing data. 2011 , 98, 253-9		9
223	Contribution of the intestinal microbiota to human health: from birth to 100 years of age. 2013 , 358, 323-46		44
222	Irritable bowel syndrome, gut microbiota and probiotics. 2011 , 17, 252-66		127
221	Commensal bacteria: the link between IBS and IBD?. 2011 , 14, 497-503		9
220	Post-infectious irritable bowel syndrome: the past, the present and the future. 2011 , 26 Suppl 3, 94-101		49
219	PhyloChip microarray analysis reveals altered gastrointestinal microbial communities in a rat model of colonic hypersensitivity. <i>Neurogastroenterology and Motility</i> , 2011 , 23, 169-77, e41-2	4	26
218	High polyphenol, low probiotic diet for weight loss because of intestinal microbiota interaction. 2011 , 189, 1-8		122
217	Irritables Kolon bei Kindern. 2011 , 159, 1206-1212		

216	Intestinal microbiota in human health and disease: the impact of probiotics. 2011 , 6, 209-40	453
215	Real-time PCR analysis of enteric pathogens from fecal samples of irritable bowel syndrome subjects. 2011 , 3, 6	47
214	Detection and Identification of Probiotic Microorganisms and Other Beneficial Organisms from the Human GI Tract. 2011 , 57-86	
213	High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. 2011 , 4, 43-8	21
212	Microbial community and metabolomic comparison of irritable bowel syndrome faeces. 2011 , 60, 817-827	164
211	Probiotics and irritable bowel syndrome. 2012 , 23,	4
210	The gut microbiota and irritable bowel syndrome: friend or foe?. 2012 , 2012, 151085	109
209	Reizdarmsyndrom. 2012 , 9, 41-49	1
208	Functional analysis of colonic bacterial metabolism: relevant to health?. 2012 , 302, G1-9	137
207	Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome. 2012 , 107, 1740-51	131
206	The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. 2012 , 107, 28-35; quiz 36	200
205	Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. 2012 , 46, 261-74	297
204	Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. <i>Nutrients</i> , 2012 , 4, 1095-119	6.7 417
203	Disruption of the human gut microbiota following Norovirus infection. 2012 , 7, e48224	83
202	An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome. 2012 , 18, 258-68	112
201	Can Colonoscopy Aspirates be a Substitute for Fecal Samples in Analyses of the Intestinal Microbiota?. 2012 , 31, 71-6	1
200	The murine caecal microRNA signature depends on the presence of the endogenous microbiota. 2012 , 8, 171-86	85
199	Human microbiome in health and disease. 2012 , 7, 99-122	330

198	Reizdarmsyndrom. 2012 , 34, 157-166		1
197	Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome. 2012 , 4, 242-7		70
196	Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2012 , 24, 521-30, e248	4	270
195	Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2012 , 24, 513-20, e246-7	4	164
194	Abdominal bloating and distension: what is the role of the microbiota. 2012 , 57, 4-8		10
193	Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. 2013 , 48, 995-1009		54
192	Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome. 2013 , 28, 1624-31		60
191	Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome. 2013 , 86, 581-9		59
190	Intestinal microbiota and its role in irritable bowel syndrome (IBS). 2013 , 15, 323		91
189	Colonization resistance: battle of the bugs or Mflage Trois with the host?. 2013 , 9, e1003730		57
188	Metabolomics as a diagnostic tool in gastroenterology. 2013 , 4, 97-107		55
187	Altered colonic function and microbiota profile in a mouse model of chronic depression. <i>Neurogastroenterology and Motility</i> , 2013 , 25, 733-e575	4	182
186	The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. <i>Gut Microbes</i> , 2013 , 4, 17-27	8.8	155
185	Fecal excretion of <i>Bifidobacterium infantis</i> 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. <i>Gut Microbes</i> , 2013 , 4, 201-11	8.8	52
184	Intestinal microbiota in functional bowel disorders: a Rome foundation report. 2013 , 62, 159-76		607
183	Unraveling the ties between irritable bowel syndrome and intestinal microbiota. 2014 , 20, 2470-81		54
182	The microbiota-gut-brain axis in functional gastrointestinal disorders. <i>Gut Microbes</i> , 2014 , 5, 419-29	8.8	86
181	Dysbiosis in the inflamed intestine: chance favors the prepared microbe. <i>Gut Microbes</i> , 2014 , 5, 71-3	8.8	116

180	Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review. 2014 , 79, 96-134	29
179	Why related bacterial species bloom simultaneously in the gut: principles underlying the Qike will to likeQoncept. 2014 , 16, 179-84	66
178	The impact of microbiota on brain and behavior: mechanisms & therapeutic potential. 2014 , 817, 373-403	197
177	Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review. 2014 , 79, 96-134	1
176	Irritable bowel syndrome: emerging paradigm in pathophysiology. 2014 , 20, 2456-69	88
175	Irritable bowel syndrome: a microbiome-gut-brain axis disorder?. 2014 , 20, 14105-25	195
174	Brain-gut microbiome interactions and functional bowel disorders. 2014 , 146, 1500-12	277
173	Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome. 2014 , 5, 247-61	31
172	The first 1000 cultured species of the human gastrointestinal microbiota. 2014 , 38, 996-1047	616
171	The microbiome: stress, health and disease. 2014 , 25, 49-74	285
170	Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. 2014 , 63, 1737-45	207
169	Infectious diarrhea: an overview. 2014 , 16, 399	23
168	The future of probiotics for disorders of the brain-gut axis. 2014 , 817, 417-32	13
167	Current and emerging pharmacotherapeutic options for irritable bowel syndrome. 2014 , 74, 1849-1870	19
166	[Pain therapy in irritable bowel syndrome]. 2014 , 28, 289-93	0
165	Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia. 2014 , 39, 624-44	85
164	Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. 2015 , 5, 12693	173
163	Dysbiosis of the gut microbiota in disease. 2015 , 26, 26191	604

162	Probiotics in Irritable Bowel Syndrome: The Science and the Evidence. 2015 , 49 Suppl 1, S60-4	20
161	Recent developments in the pathophysiology of irritable bowel syndrome. 2015 , 21, 7621-36	64
160	Gut microbiota as potential orchestrators of irritable bowel syndrome. 2015 , 9, 318-31	86
159	Metabolic and Microbial Modulation of the Large Intestine Ecosystem by Non-Absorbed Diet Phenolic Compounds: A Review. 2015 , 20, 17429-68	126
158	Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. 2015 , 8, 309-25	53
157	Characterization of the human gut microbiome during travelers' diarrhea. <i>Gut Microbes</i> , 2015 , 6, 110-9	8.8 85
156	Gnotobiology and the Study of Complex Interactions between the Intestinal Microbiota, Probiotics, and the Host. 2015 , 109-133	4
155	Characterization of the bacterial gut microbiota of piglets suffering from new neonatal porcine diarrhoea. 2015 , 11, 139	49
154	No difference in small bowel microbiota between patients with irritable bowel syndrome and healthy controls. 2015 , 5, 8508	49
153	Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena?. 2015 , 110, 278-87	225
152	Recent advances in the diagnosis of irritable bowel syndrome. 2015 , 9, 1161-74	9
151	Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome. 2015 , 16, 2781-92	6
150	Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. 2015 , 12, 36-49	115
149	Dietary Interventions and Irritable Bowel Syndrome. 2016 , 423-438	1
148	Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. 2016 , 22, 2219-41	176
147	Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome. 2016 , 22, 8137-48	43
146	Dietary Shifts May Trigger Dysbiosis and Mucous Stools in Giant Pandas (<i>Ailuropoda melanoleuca</i>). 2016 , 7, 661	21
145	The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties. 2016 , 6, 39399	55

144	Fecal Microbiota and Metabolome in a Mouse Model of Spontaneous Chronic Colitis: Relevance to Human Inflammatory Bowel Disease. 2016 , 22, 2767-2787		28
143	The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. 2016 , 34, 269-78		72
142	Randomized clinical trial: The effect of fermented milk with the probiotic cultures <i>Lactobacillus acidophilus</i> La-5 and <i>Bifidobacterium</i> BB-12 and Beneo dietary fibres on health-related quality of life and the symptoms of irritable bowel syndrome in adults. 2016 , 24, 549-557		14
141	Anaerobic choline metabolism in microcompartments promotes growth and swarming of <i>Proteus mirabilis</i> . 2016 , 18, 2886-98		31
140	Interplays Between Gut Microbiota and Gene Expression Regulation by miRNAs: Towards a Symbiotic Vision of Host and Guest. 2016 , 53-65		1
139	Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. <i>Gut Microbes</i> , 2016 , 7, 397-413	8.8	40
138	The gut microbiota: A treasure for human health. 2016 , 34, 1210-1224		108
137	A tale of two sites: how inflammation can reshape the microbiomes of the gut and lungs. 2016 , 100, 943-950		49
136	Role of NLRP3 inflammasome in <i>Bifidobacterium longum</i> -regulated visceral hypersensitivity of postinfectious irritable bowel syndrome. 2016 , 44, 1933-1937		11
135	Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2016 , 28, 1330-40	4	70
134	Extrusion of barley and oat influence the fecal microbiota and SCFA profile of growing pigs. 2016 , 7, 1024-32		23
133	Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?. 2016 , 9, 199-212		44
132	Signatures of early frailty in the gut microbiota. 2016 , 8, 8		200
131	Gut Microbiota and IBS. 2016 , 557-566		1
130	Relationship Between Microbiota of the Colonic Mucosa vs Feces and Symptoms, Colonic Transit, and Methane Production in Female Patients With Chronic Constipation. 2016 , 150, 367-79.e1		173
129	Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. 2017 , 49, 331-337		131
128	Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. 2017 , 9,		246
127	Understanding the Gut Microbiota in Inflammatory and Functional Gastrointestinal Diseases. 2017 , 79, 857-867		31

126	Inhibition of corticotropin-releasing hormone receptor 1 and activation of receptor 2 protect against colonic injury and promote epithelium repair. 2017 , 7, 46616	30
125	Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome. 2017 , 5, 49	146
124	Review of mechanisms of deoxynivalenol-induced anorexia: The role of gut microbiota. 2017 , 37, 1021-1029	20
123	The Microbiome in Neurogastroenterology. 2017 , 53-70	
122	Irritable bowel syndrome: a gut microbiota-related disorder?. 2017 , 312, G52-G62	102
121	Post-Infectious Irritable Bowel Syndrome. 2017 , 19, 56	26
120	Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. 2017 , 279, 70-89	515
119	Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome. 2017 , 96, 29-38	76
118	Dysbiotic Proteobacteria expansion: a microbial signature of epithelial dysfunction. 2017 , 39, 1-6	220
117	Close association between intestinal microbiota and irritable bowel syndrome. 2017 , 36, 2303-2317	11
116	Analysis of the gut microbiome and plasma short-chain fatty acid profiles in a spontaneous mouse model of metabolic syndrome. 2017 , 7, 15876	60
115	Fecal microbial characterization of hospitalized patients with suspected infectious diarrhea shows significant dysbiosis. 2017 , 7, 1088	24
114	Human Gut Microbiota: Toward an Ecology of Disease. 2017 , 8, 1265	74
113	Systematic review and meta-analysis of traditional Chinese medicine in the treatment of constipation-predominant irritable bowel syndrome. 2017 , 12, e0189491	15
112	Alterations of the Gut Microbiota in Hashimoto's Thyroiditis Patients. 2018 , 28, 175-186	73
111	The germ-organ theory of non-communicable diseases. 2018 , 16, 103-110	68
110	Gas chromatography/mass spectrometry based metabolomic study in a murine model of irritable bowel syndrome. 2018 , 24, 894-904	25
109	Colonocyte metabolism shapes the gut microbiota. 2018 , 362,	205

108	Microbiota dysbiosis and its pathophysiological significance in bowel obstruction. 2018 , 8, 13044	19
107	Effect of GG supernatant on serotonin transporter expression in rats with post-infectious irritable bowel syndrome. 2018 , 24, 338-350	25
106	Lacto-fermented sauerkraut improves symptoms in IBS patients independent of product pasteurisation - a pilot study. 2018 , 9, 5323-5335	32
105	Altered Intestinal Microbiota with Increased Abundance of <i>Is</i> Associated with High Risk of Diarrhea-Predominant Irritable Bowel Syndrome. 2018 , 2018, 6961783	56
104	Role of Gut Microbiota-Gut Hormone Axis in the Pathophysiology of Functional Gastrointestinal Disorders. 2018 , 24, 367-386	41
103	A double blind, placebo-controlled, randomized clinical trial that breast milk derived- BNR17 mitigated diarrhea-dominant irritable bowel syndrome. 2018 , 62, 179-186	28
102	Intestinal-Based Diseases and Peripheral Infection Risk Associated with Gut Dysbiosis: Therapeutic use of Pre- and Probiotics and Fecal Microbiota Transplantation. 2018 , 197-288	
101	Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. 2019 , 16, 605-616	438
100	Soil fungal communities vary with invasion by the exotic <i>Spartina alternifolia</i> Loisel. in coastal salt marshes of eastern China. 2019 , 442, 215-232	8
99	Identification of Gut Microbiota and Metabolites Signature in Patients With Irritable Bowel Syndrome. 2019 , 9, 346	17
98	Specific increase of <i>Fusobacterium</i> in the faecal microbiota of neonatal calves infected with <i>Cryptosporidium parvum</i> . 2019 , 9, 12517	13
97	Dysbiosis: from fiction to function. 2019 , 317, G602-G608	27
96	Beneficial Effects of Dietary Polyphenols on Gut Microbiota and Strategies to Improve Delivery Efficiency. <i>Nutrients</i> , 2019 , 11,	6.7 170
95	Microbiota-nourishing Immunity and Its Relevance for Ulcerative Colitis. 2019 , 25, 811-815	23
94	Irritable bowel syndrome: a new therapeutic target when treating obesity?. 2019 , 18, 395-399	9
93	The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy. 2019 , 10, 1136	101
92	Evidence for an association of gut microbial <i>Clostridia</i> with brain functional connectivity and gastrointestinal sensorimotor function in patients with irritable bowel syndrome, based on tripartite network analysis. 2019 , 7, 45	57
91	Glutamatergic Signaling Along The Microbiota-Gut-Brain Axis. 2019 , 20,	81

90	Regulatory effect of Garidisan on dysbiosis of the gut microbiota in the mouse model of ulcerative colitis induced by dextran sulfate sodium. 2019 , 19, 329	1
89	Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome. 2019 , 132, 889-904	22
88	Flaxseed oil supplementation improves intestinal function and immunity, associated with altered intestinal microbiome and fatty acid profile in pigs with intrauterine growth retardation. 2019 , 10, 8149-8160	9
87	What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. 2019 , 7,	825
86	Molecular ecology of the yet uncultured bacterial Ct85-cluster in the mammalian gut. 2020 , 62, 102104	1
85	Preventive antibiotic treatment of calves: emergence of dysbiosis causing propagation of obese state-associated and mobile multidrug resistance-carrying bacteria. 2020 , 13, 669-682	8
84	Gut Microbial Metabolites and Biochemical Pathways Involved in Irritable Bowel Syndrome: Effects of Diet and Nutrition on the Microbiome. 2020 , 150, 1012-1021	16
83	Gut Microbiota and Epilepsy: A Systematic Review on Their Relationship and Possible Therapeutics. 2020 , 11, 3488-3498	12
82	Colchicine increases intestinal permeability, suppresses inflammatory responses, and alters gut microbiota in mice. 2020 , 334, 66-77	5
81	Gut Microbiota-Bile Acid Crosstalk in Diarrhea-Irritable Bowel Syndrome. 2020 , 2020, 3828249	13
80	The pathophysiology of bile acid diarrhoea: differences in the colonic microbiome, metabolome and bile acids. 2020 , 10, 20436	11
79	Rotavirus infection induces glycan availability to promote ileum-specific changes in the microbiome aiding rotavirus virulence. <i>Gut Microbes</i> , 2020 , 11, 1324-1347	8.8 25
78	Tryptophan Metabolites Along the Microbiota-Gut-Brain Axis: An Interkingdom Communication System Influencing the Gut in Health and Disease. 2020 , 13, 1178646920928984	42
77	Causes Microbial Dysbiosis and Exacerbates Visceral Hypersensitivity in a Colonization-Independent Manner. 2020 , 11, 1281	12
76	Microbial management. 2020 , 369, 153	2
75	Colitis-Induced Microbial Perturbation Promotes Postinflammatory Visceral Hypersensitivity. 2020 , 10, 225-244	12
74	Gut Epithelial Metabolism as a Key Driver of Intestinal Dysbiosis Associated with Noncommunicable Diseases. 2020 , 88,	7
73	Genistein Reduces the Risk of Local Mammary Cancer Recurrence and Ameliorates Alterations in the Gut Microbiota in the Offspring of Obese Dams. <i>Nutrients</i> , 2021 , 13,	6.7 7

72	The Role of Acupuncture on the Gut-Brain-Microbiota Axis in Irritable Bowel Syndrome. 2021 , 49, 285-314	5
71	Dysbiosis of the shrimp (<i>Penaeus monodon</i>) gut microbiome with AHPND outbreaks revealed by 16S rRNA metagenomics analysis. 2021 , 52, 3336-3349	7
70	Do Rural Second Homes Shape Commensal Microbiota of Urban Dwellers? A Pilot Study among Urban Elderly in Finland. 2021 , 18,	2
69	Altered interaction between enteric glial cells and mast cells in the colon of women with irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2021 , 33, e14130	4 3
68	The Habitat Filters of Microbiota-Nourishing Immunity. 2021 , 39, 1-18	4
67	Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms. <i>Nutrients</i> , 2021 , 13,	6.7 8
66	Irritable Bowel and Bacterial Overgrowth Syndromes: a Bacterial Link Hypothesis of Functional Disease. 2021 , 31, 54-63	3
65	Significance of the Gut Microbiota in Acute Kidney Injury. 2021 , 13,	5
64	Impact of diet on human gut microbiome and disease risk. 2021 , 41, 100845	4
63	Shiftwork, functional bowel symptoms, and the microbiome. 2021 , 9, e11406	1
62	Leveraging 16S rRNA Microbiome Sequencing Data to Identify Bacterial Signatures for Irritable Bowel Syndrome. 2021 , 11, 645951	4
61	CBP22, a Novel Bacteriocin Isolated from ZJU-F1, Protects against LPS-Induced Intestinal Injury through Maintaining the Tight Junction Complex. 2021 , 2021, 8032125	2
60	Effect of Cigarette Smoke on Gut Microbiota: State of Knowledge. 2021 , 12, 673341	11
59	relieve the visceral hypersensitivity in mice induced by infection with chronic stress. 2021 , 9, e11585	0
58	Washed Microbiota Transplantation Accelerates the Recovery of Abnormal Changes by Light-Induced Stress in Tree Shrews. 2021 , 11, 685019	0
57	Influence of low FODMAP-gluten free diet on gut microbiota alterations and symptom severity in Iranian patients with irritable bowel syndrome. <i>BMC Gastroenterology</i> , 2021 , 21, 292	3 3
56	Crosstalk Between Intestinal Microbiota Derived Metabolites and Tissues in Allogeneic Hematopoietic Cell Transplantation. 2021 , 12, 703298	0
55	Co-factors, Microbes, and Immunogenetics in Celiac Disease to Guide Novel Approaches for Diagnosis and Treatment. 2021 , 161, 1395-1411.e4	4

54	Microbiota and the irritable bowel syndrome. 2021 ,	0
53	Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome. 2021 , 11, 729346	9
52	Association of Fecal Microbiota with Irritable Bowel Syndrome-Diarrhea and Effect of Traditional Chinese Medicine for Its Management. 2021 , 2021, 7035557	1
51	Human milk oligosaccharides alleviate stress-induced visceral hypersensitivity and associated microbiota dysbiosis. 2022 , 99, 108865	2
50	The Human Microbiome. 2021 , 1-28	
49	Metabonomics and systems biology. 2015 , 1277, 245-55	7
48	Characteristics of the bacterial microbiome in association with common intestinal parasites in irritable bowel syndrome. 2018 , 9, 161	44
47	Overgrowth of the indigenous gut microbiome and irritable bowel syndrome. 2014 , 20, 2449-55	12
46	Methodological issues in the study of intestinal microbiota in irritable bowel syndrome. 2014 , 20, 8821-36	14
45	Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. 2014 , 20, 8886-97	60
44	Use of rifaximin in gastrointestinal and liver diseases. 2016 , 22, 6638-51	28
43	Gastrointestinal neuromuscular apparatus: An underestimated target of gut microbiota. 2016 , 22, 9871-9879	16
42	Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome. 2020 , 26, 7153-7172	15
41	Risk Factors for Gut Dysbiosis in Early Life. 2021 , 9,	6
40	Gut-microbiota derived bioactive metabolites and their functions in host physiology. 2021 , 37, 105-153	3
39	The Intestinal Microbiota and Intestinal Disease: Irritable Bowel Syndrome. 2012 , 211-222	
38	Irritable Bowel Syndrome and Microbial Pathogenesis. 2014 , 1-27	
37	Modulation of the Gut Ecosystem in Irritable Bowel Syndrome. 2014 , 55-73	

36	A Clostridia-rich microbiota contributes to increased excretion of bile acids in diarrhea-predominant irritable bowel syndrome.		0
35	Phenotypic features of patients with post-infectious irritable bowel syndrome. 2019 , 92, 239-245		1
34	Neuro-consequences of the spaceflight environment. 2021 , 132, 908-908		8
33	Fecal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease patients with irritable bowel syndrome-type symptoms. <i>BMC Gastroenterology</i> , 2021 , 21, 433	3	0
32	AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms.. <i>Gut Microbes</i> , 2022 , 14, 2022997	8.8	2
31	Effects of Dietary Choline Levels During Pregnancy on Reproductive Performance, Plasma Metabolome and Gut Microbiota of Sows.. <i>Frontiers in Veterinary Science</i> , 2021 , 8, 771228	3.1	
30	Analysis of Psychological and Gut Microbiome Characteristics in Patients With Non-erosive Reflux Disease.. <i>Frontiers in Psychiatry</i> , 2021 , 12, 741049	5	
29	Gut microbiome alterations in hereditary angioedema.. <i>Annals of Allergy, Asthma and Immunology</i> , 2022 ,	3.2	0
28	Gut Microbiome Composition as the Key Factor for Immunomodulation in the Host. 2022 , 169-185		
27	Gut Microbiome and the Role of Metabolites in the Study of Graves Disease.. <i>Frontiers in Molecular Biosciences</i> , 2022 , 9, 841223	5.6	0
26	Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) Juni 2021 AWMF-Registriernummer: 021/016. <i>Zeitschrift Fur Gastroenterologie</i> 2021 , 59, 1323-1415	1.6	4
25	Data_Sheet_1.doc. 2019 ,		
24	Data_Sheet_2.doc. 2019 ,		
23	Data_Sheet_3.doc. 2019 ,		
22	Image_1.TIF. 2019 ,		
21	Data_Sheet_1.pdf. 2020 ,		
20	Data_Sheet_2.PDF. 2020 ,		
19	Acromegaly is associated with a distinct oral and gut microbiota.. <i>Pituitary</i> , 2022 , 1	4.3	0

18	Intestinal Dysbiosis in Patients with Histamine Intolerance.. <i>Nutrients</i> , 2022 , 14,	6.7	2
17	Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids.. <i>Neurogastroenterology and Motility</i> , 2022 , e14390	4	0
16	Kimchi improves irritable bowel syndrome: results of a randomized, double-blind placebo-controlled study. <i>Food and Nutrition Research</i> ,	3.1	1
15	The Effect of Short-Term Consumption of Lactic Acid Bacteria on the Gut Microbiota in Obese People. 2022 , 14, 3384		0
14	Association of abnormal bowel health with major chronic diseases and risk of mortality. 2022 , 75, 39-46		0
13	Gut microbiota in gastrointestinal diseases. 2022 ,		1
12	Microbial Interdomain Interactions Delineate the Disruptive Intestinal Homeostasis in <i>Clostridioides difficile</i> Infection.		0
11	The dietary treatment of histamine intolerance reduces the abundance of some histamine-secreting bacteria of the gut microbiota in histamine intolerant women. A pilot study. 9,		0
10	Biofilms and Benign Colonic Diseases. 2022 , 23, 14259		1
9	Soil nutrients shape the composition and function of fungal communities in abandoned ancient rice terraces. 2023 , 329, 117064		0
8	The Microbiome in Neurogastroenterology. 2022 , 73-93		0
7	The effect of gut microbiota dysbiosis on patients with preeclampsia. 12,		0
6	New insights into the mechanisms of high-fat diet mediated gut microbiota in chronic diseases.		0
5	Exploring the mechanism of Xingpi Capsule in diarrhea predominant-irritable bowel syndrome treatment based on multiomics technology. 2023 , 111, 154653		0
4	Gut Microbiota: A Future Clinical Magic Bullet to Manifest Pathogenic Disease in the Current Future. 2023 , 17, 51-68		0
3	Effects of Different Combinations of Sodium Butyrate, Medium-Chain Fatty Acids and Omega-3 Polyunsaturated Fatty Acids on the Reproductive Performance of Sows and Biochemical Parameters, Oxidative Status and Intestinal Health of Their Offspring. 2023 , 13, 1093		0
2	Characteristics and properties of a polysaccharide isolated from <i>Wolfiporia cocos</i> as potential dietary supplement for IBS. 10,		0
1	Gut Microbiota and Its Role in Anti-aging Phenomenon: Evidence-Based Review.		0

